menu
    • menu
    [{"orgOrder":0,"company":"Handa Pharmaceuticals","sponsor":"Xspray Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Handa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Handa Pharmaceuticals \/ Handa Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Handa Pharmaceuticals \/ Handa Pharmaceuticals"},{"orgOrder":0,"company":"Handa Pharmaceuticals","sponsor":"Nanocopoeia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Handa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Handa Pharmaceuticals \/ Handa Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Handa Pharmaceuticals \/ Handa Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Handa Pharmaceuticals

    Menu

    Handa Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Handa Pharmaceuticals

                            Taiwan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Handa Pharmaceuticals

                            Taiwan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Xspray Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Xspray Pharma Signs License Agreement with Handa Therapeutics

                            Details : Xspray granted Handa a non-exclusive license to certain Xspray patents for the commercialization of Handa’s Phyrago (dasatinib) product in the U.S. and, in the future, selected Asian markets.

                            Product Name : Phyrago

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 12, 2025

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Xspray Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Handa Pharmaceuticals

                            Taiwan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Handa Pharmaceuticals

                            Taiwan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Nanocopoeia

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Handa Acquires FDA-Approved PHYRAGO (dasatinib) Tablets for CML

                            Details : Handa Therapeutics has acquired Phyrago (dasatinib) from Nanocopoeia. This FDA-approved product is indicated for treating Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia.

                            Product Name : Phyrago

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 15, 2025

                            Lead Product(s) : Dasatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Nanocopoeia

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth